文献速递胸部肿瘤

BFAST研究:血液NGS指导ALK阳性NSCLC一线阿来替尼治疗II期结果

Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort.
PubMed 文献 · J Thorac Oncol · 2021-07-24

BFAST是一项开放标签、多队列研究,前瞻性评估血液NGS检测可靶向基因改变与靶向/免疫治疗疗效的关系。本文报告ALK阳性队列:2219例筛查患者中血液NGS成功率98.6%,119例(5.4%)ALK阳性,87例入组接受阿来替尼600mg每日两次。研究者评估确认ORR 87.4%,独立评审ORR 92.0%,基线CNS转移患者ORR 91.4%,12个月PFS率78.4%,安全性符合已知特征。

要点

  • 血液NGS筛查ALK融合成功率高,可用于指导一线治疗决策
  • 阿来替尼一线治疗ALK阳性NSCLC确认ORR达87.4%
  • 基线CNS转移患者研究者评估ORR为91.4%

核心结论

  • 血液NGS可作为ALK阳性NSCLC临床决策的方法,阿来替尼一线治疗显示高缓解率和颅内活性。

研究设计与样本

  • BFAST为正在进行的开放标签、多队列研究,前瞻性评估血液NGS检测可靶向基因改变与靶向/免疫治疗疗效的关系。
  • 本报告为ALK阳性队列:年龄≥18岁、IIIB或IV期NSCLC、血液NGS(FoundationACT杂交捕获技术)检出ALK重排的患者接受阿来替尼600mg每日两次。
  • 允许无症状或经治疗的CNS转移;主要终点为研究者评估ORR(RECIST 1.1)。

主要发现

  • 共筛查2219例患者,血液NGS在98.6%的病例中产生结果,119例(5.4%)为ALK阳性,87例入组接受阿来替尼。
  • 中位随访12.6个月(范围2.6-18.7),研究者评估确认ORR为87.4%(95%CI 78.5-93.5),独立评审ORR为92.0%(95%CI 84.1-96.7)。
  • 研究者确认的12个月缓解持续率为75.9%(95%CI 63.6-88.2)。
  • 35例(40%)基线CNS疾病患者的研究者评估ORR为91.4%(95%CI 76.9-98.2)。
  • 中位PFS未达到,研究者评估的12个月PFS率为78.4%(95%CI 69.1-87.7),安全性数据与阿来替尼已知耐受性一致。

临床怎么用

  • 对初治晚期或转移性NSCLC患者,可考虑血液NGS检测ALK融合以指导阿来替尼一线治疗。
  • 阿来替尼600mg每日两次在ALK阳性患者中显示高ORR和12个月PFS率,包括基线CNS转移患者。

局限性

  • 本研究为单臂II期队列,无对照臂。
  • 中位随访12.6个月,中位PFS未达到,长期生存数据尚不成熟。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The Blood First Assay Screening Trial is an ongoing open-label, multicohort study, prospectively evaluating the relationship between blood-based next-generation sequencing (NGS) detection of actionable genetic alterations and activity of targeted therapies or immunotherapy in treatment-naive advanced or metastatic NSCLC. We present data from the ALK-positive cohort. METHODS: Patients aged more than or equal to 18 years with stage IIIB or IV NSCLC and ALK rearrangements detected by blood-based NGS using hybrid capture technology (FoundationACT) received alectinib 600 mg twice daily. Asymptomatic or treated central nervous system (CNS) metastases were permitted. Primary end point was investigator-assessed objective response rate (ORR; Response Evaluation Criteria in Solid Tumors version 1.1). Secondary end points were independent review facility-assessed ORR, duration of response, progression-free survival (PFS), overall survival, and safety. Exploratory end points were investigator-assessed ORR in patients with baseline CNS metastases and relationship between circulating biomarkers and response. RESULTS: In total, 2219 patients were screened and blood-based NGS yielded results in 98.6% of the cases. Of these, 119 patients (5.4%) had ALK-positive disease; 87 were enrolled and received alectinib. Median follow-up was 12.6 months (range: 2.6-18.7). Confirmed ORR was 87.4% (95% confidence interval [CI]: 78.5-93.5) by investigator and 92.0% (95% CI: 84.1-96.7) by independent review facility. Investigator-confirmed 12-month duration of response was 75.9% (95% CI: 63.6-88.2). In 35 patients (40%) with baseline CNS disease, investigator-assessed ORR was 91.4% (95% CI: 76.9-98.2). Median PFS was not reached; 12-month investigator-assessed PFS was 78.4% (95% CI: 69.1-87.7). Safety data were consistent with the known tolerability profile of alectinib. CONCLUSIONS: These results reveal the clinical application of blood-based NGS as a method to inform clinical decision-making in ALK-positive NSCLC.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Dziadziuszko R, Mok T, Peters S, et al. Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort. J Thorac Oncol. 2021. PMID: 34311110. doi:10.1016/j.jtho.2021.07.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。